Our latest paper on ‘Incidental findings in low dose CT lung cancer screening of high-risk smokers’.
Data from our initial pilot study which has helped us develop more robust protocols for management of incidental findings locally https://t.co/7BoJl5AzZK
#lungcancer#screening
Entrectinib prolonged survival in #ROS1 TKI-naïve pts w/ ROS1+ #NSCLC according to an updated integrated analysis by Drilon et al. Modest efficacy observed in pts w/ CNS-only progression post-crizotinib https://t.co/wZqR96a5Vi #JTOCRR#LCSM@JTOonline @OncologyAdvance
@marklewismd@drkiwicj@YouTube Oh ha ha mix of COVID brain and autocorrect with the *too... maybe a good sign for recovery that I noticed?? Think my early signs of recovery should be rewarded with a cover version by you both!?
Improved pathologic staging starts with better communication and other multidisciplinary efforts. Mary Beth Beasley, MD, explores the topic in ILCN: https://t.co/uQFz5tVpfz @MountSinai_Path#LCSM
The inspiring @NarjustDumaMD cites “being human” as her greatest credential as an oncologist, explaining that reducing cancer care disparities begins with an honest assessment of our own biases/less patient-blaming (e.g. “non-compliant” may be code for poor medical communication)
#LungCancer screening in the US: primary care physicians’ knowledge, practices and perceived barriers. The survey by Kota et al. indicated cost, insurance and awareness as top barriers. https://t.co/Xx5DenmCCF #JTOCRR#LCSM#LDCT@JTOonline @OncologyAdvance
Early Registration for #WCLC22 closes on May 4, 2022! Join the world's largest international gathering of clinicians, researchers, & scientists in the field of #lungcancer & thoracic oncology. Register today: https://t.co/E5V1z9qO3u #LCSM
@thecwordradio @drkiwikate @glaking@cameroncologist Hi Helen. I dont know what he is up to now but Dr Mark Winstanley would be an awesome person to talk to. Based at Starship CAB unit. Working with AYA with cancer.
Lung cancer is a complex disease w/many causes; Largely overlooked is the relationship between air pollution & #lungcancer. We support advocacy for clean air & urge health care organizations & relevant legislative bodies to support our policy statement: https://t.co/PUZAOFSz3t
From their network meta-analysis of Asian pts w/ advanced EGFR L858R NSCLC, Chan et al. indicated no overall survival benefit from first-line EGFR TKIs and combination therapies vs. conventional chemotherapies https://t.co/rq78FSeuMm @JTOonline @OncologyAdvance #JTOCRR#LCSM